<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03464344</url>
  </required_header>
  <id_info>
    <org_study_id>RC31/16/8919</org_study_id>
    <secondary_id>2017-A01524-49</secondary_id>
    <nct_id>NCT03464344</nct_id>
  </id_info>
  <brief_title>Cortical Superficial Siderosis and Risk of Recurrent Intracerebral Hemorrhage in Cerebral Amyloid Angiopathy.</brief_title>
  <acronym>CORELIA</acronym>
  <official_title>COrtical Superficial Siderosis and REcurrent Lobar Intracerebral Hemorrhage in Cerebral Amyloid Angiopathy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cerebral amyloid angiopathy (CAA) is a major cause of lobar intracerebral hemorrhage (ICH) in
      the elderly with high risk of recurrence.

      The investigators aim to determine the relationship between cortical superficial siderosis
      (cSS), a MRI hemorrhagic marker of CAA and the risk of symptomatic ICH recurrence in a
      multicentric prospective cohort of patients with acute lobar ICH related to CAA. The
      investigators hypothesize that patients with cSS have an increased risk of recurrent
      symptomatic ICH relative to those without cSS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with acute lobar ICH fulfilling the Boston criteria for probable or possible CAA
      will be enrolled within 30 days after ICH onset. Brain MRI performed at baseline will be
      analyzed blinded to clinical data. Patients with presence of cSS will be compared with those
      without cSS.

      During a systematic follow-up of 24 months, patients will undergo neurological,
      neuropsychological and MRI evaluation. We will compare the rate of recurrent symptomatic ICH
      at 24 months in patients with vs. without cSS.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2018</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrent symptomatic intracerebral hemorrhage at 24 months</measure>
    <time_frame>24 months</time_frame>
    <description>Recurrent symptomatic intracerebral haemorrhage is defined as a further intracerebral hemorrhage documented by CT scan or MRI, associated with new neurologic symptoms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrent symptomatic ICH at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Recurrent symptomatic intracerebral haemorrhage is defined as a further intracerebral hemorrhage documented by CT scan or MRI, associated with new neurologic symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transient Focal Neurological Episodes (TFNE) at 12 and 24 months</measure>
    <time_frame>12 and 24 months</time_frame>
    <description>TFNE was defined as transient (≤24 hours), with fully resolving, focal neurological symptoms that had no known alternative explanation other than CAA (e.g., structural brain lesion, atrial fibrillation, extracranial, or intracranial stenosis)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality or dependance at 12 and 24 months</measure>
    <time_frame>12 and 24 months</time_frame>
    <description>Mortality and dependence defined by a modified Rankin scale &gt;2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive decline at 12 and 24 months</measure>
    <time_frame>12 and 24 months</time_frame>
    <description>moderate or severe vascular cognitive disorders (VCD) according to the VASCOG criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New MRI hemorrhagic lesion at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Presence of new symptomatic or asymptomatic hemorrhagic lesion (ICH, microbleeds, convexity subarachnoid hemorrhage) on follow-up MRI at 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extent of cortical superficial siderosis at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Extent of cSS is assessed on follow up MRI at 12 months according to the current guidelines: 0: no cSS; 1: focal cSS (restricted to ≤3 sulci); 2: disseminated cSS (≥4 sulci).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>frequency of APOE ε2 and ε4 allele</measure>
    <time_frame>baseline</time_frame>
    <description>frequency of both ε2 and ε4 allele on Apolipoprotein E (APOE) genotype at baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">169</enrollment>
  <condition>Cerebral Amyloid Angiopathy</condition>
  <arm_group>
    <arm_group_label>Patients with cortical superficial siderosis.</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>During a systematic follow-up of 24 months, patients will undergo neurological, neuropsychological and MRI evaluation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients without cortical superficial siderosis</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>During a systematic follow-up of 24 months, patients will undergo neurological, neuropsychological and MRI evaluation</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>neurological, neuropsychological and MRI evaluation</intervention_name>
    <description>neurological, neuropsychological and MRI evaluation</description>
    <arm_group_label>Patients with cortical superficial siderosis.</arm_group_label>
    <arm_group_label>Patients without cortical superficial siderosis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Lobar ICH within 30 days after onset

          -  Available brain MRI sequences of adequate quality including fluid-attenuated inversion
             recovery (FLAIR) and T2*-weighted gradient-recalled echo (T2*-GRE) sequences.

          -  Modified Boston criteria for probable or possible CAA

          -  Age ≥ 55 years

          -  Written consent

        Exclusion Criteria:

          -  Secondary brain hemorrhage : vascular malformation (arteriovenous malformation,
             aneurysm, cavernous); cerebral veinous thrombosis; brain tumor; coagulopathy;
             vasculitis; hemorrhagic infarction,

          -  Infratentorial siderosis

          -  Contraindications to MRI

          -  Neurosurgical intervention before inclusion,

          -  Impaired vision, hearing disability or speech disorder that can compromise a
             comprehensive neuropsychological examination

          -  Progressive neoplasm

          -  Patient without affiliation to the french social security

          -  Patient under guardianship
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolas RAPOSO, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Toulouse</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicolas RAPOSO, MD</last_name>
    <phone>5 61 77 76 40</phone>
    <phone_ext>33</phone_ext>
    <email>raposo.n@chu-toulouse.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Purpan. Hôpital Pierre-Paul Riquet</name>
      <address>
        <city>Toulouse cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicolas RAPOSO, MD</last_name>
    </contact>
    <investigator>
      <last_name>Christophe Cognard, PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jacques Izopet, PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claire Thalamas, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2018</study_first_submitted>
  <study_first_submitted_qc>March 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 14, 2018</study_first_posted>
  <last_update_submitted>March 7, 2018</last_update_submitted>
  <last_update_submitted_qc>March 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>intracerebral hemorrhage</keyword>
  <keyword>cerebral amyloid angiopathy</keyword>
  <keyword>cortical superficial siderosis</keyword>
  <keyword>Magnetic Resonance Imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Amyloidosis</mesh_term>
    <mesh_term>Cerebral Hemorrhage</mesh_term>
    <mesh_term>Cerebral Amyloid Angiopathy</mesh_term>
    <mesh_term>Cerebral Amyloid Angiopathy, Familial</mesh_term>
    <mesh_term>Siderosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

